UPS leans harder into drug delivery

Package delivery is usually a volume game. More boxes, more stops, more revenue. But UPS is trying to make the business less dependent on sheer parcel count and more dependent on what is inside the box — and few shipments are more valuable, or harder to replace, than prescription drugs. That is why Carol Tomé keeps talking about healthcare. In late April, after UPS reported first-quarter 2026 results, she said the company’s push into prescription-drug delivery should start paying off in the second half of this year. The timing matters because the broader economy still looks shaky, fuel costs are volatile, and UPS is deliberately walking away from lower-margin freight while trying to rebuild earnings around better business. ### Why drugs? Drug logistics is not ordinary parcel delivery. A lot of it needs temperature control, chain-of-custody tracking, specialized storage, fast handoffs, and in some cases handling for radioactive or otherwise sensitive treatments. That makes the work harder, but it also makes it stickier. A pharmacy, hospital, or drugmaker is much less likely to swap providers on price alone if the shipment is critical and tightly regulated. ### What changed now? UPS has been building this business for a while, but the push is getting more visible because the rest of the network is under pressure. First-quarter 2026 revenue came in at $21.2 billion, with operating profit of $1.27 billion, and UPS kept its full-year guidance. Even so, management framed the quarter as a transition period and pointed investors toward improvement later in the year. Healthcare is a big part of that story. ### How big is healthcare already? Big enough that it is no longer a side bet. UPS said healthcare generated $11.2 billion in revenue in 2025, almost 13% of companywide revenue. In the first quarter of 2026, that share moved above 14%. That mix shift matters because if lower-profit package volume falls away, a larger slice of the company automatically comes from more resilient, higher-margin work. ### What is UPS actually building? Basically, a colder, tighter, more specialized logistics network. The clearest move was the Andlauer Healthcare Group acquisition, announced in April 2025 for about $1.6 billion and completed in November 2025. Andlauer brought customized third-party logistics and cold-chain transportation in North America — exactly the kind of capability UPS needs if it wants to move more biologic therapies end to end. ### Why is this a hedge? Because healthcare demand does not swing like retail. People may delay discretionary purchases when the economy softens, but they do not stop needing cancer drugs, hospital supplies, or specialty treatments. Tomé has been blunt about that — she sees healthcare logistics as more recession-resistant. ### What is the catch? The catch is that specialized logistics is expensive to build and hard to run well. Cold-chain networks need infrastructure, compliance systems, and operational discipline. UPS also has to prove it can integrate acquisitions and convert that heavier healthcare mix into better margins, not just different revenue. The company has talked about a 2026 “inflection,” but investors still need to see that show up consistently in results. ### Who else should care? FedEx, drugmakers, hospitals, and anyone shipping lower-priority freight. If UPS keeps steering its network toward premium healthcare flows, that says something broader about the parcel market: the easy growth from generic e-commerce boxes is not enough anymore. Carriers want freight with better economics and stronger defenses against price competition. The bottom line is simple. UPS is trying to become less of a general box mover and more of a precision logistics company. Drug delivery is central to that bet — and the second half of 2026 is when the company says we should start seeing whether it works.